{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-052297","form_type":"8-K","ticker":"PRPH","cik":"0000868278","company_name":"ProPhase Labs, Inc.","filed_at":"2024-12-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.183293+00:00","generated_at":"2026-05-28T23:11:01.157827+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ProPhase Labs receives Nasdaq bid price deficiency notice; 180-day cure period until June 24, 2025","bullets":["Received Nasdaq letter on Dec 26, 2024 for bid price below $1.00 for 30 consecutive business days.","Has until June 24, 2025 to regain compliance by closing at $1.00+ for 10 consecutive business days.","Company qualifies for potential second 180-day extension due to stockholders' equity >= $5M.","Failure to regain compliance may lead to delisting from Nasdaq.","Management states they are working to evidence compliance, but no assurance."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-052297","json":"https://secwatch.observer/filing/0001493152-24-052297.json","markdown":"https://secwatch.observer/filing/0001493152-24-052297.md","text":"https://secwatch.observer/filing/0001493152-24-052297.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/868278/000149315224052297/0001493152-24-052297-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/868278/000149315224052297/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T23:11:01.157827+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8ef2966d40b55cffeed9e9e2fc9add20aa60e602","claim":"ProPhase Labs, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"December 26, 2024, ProPhase Labs, Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the bid price for the Company’s common stock for the last 30 consecutive business days had closed below the minimum $1.00 per share required for continued listing under Nasdaq Listing Rule 5550(a)(2). Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a 180 calendar day grace period, or until June 24, 2025, to regain compliance with the minimum bid price requirement. The continued listing standa","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/868278/000149315224052297/0001493152-24-052297-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2), 5810(c)(3)(A)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}